tbuckley/cabot-search huggingface dataset:
NIMG-02. NON-INVASIVE DETECTION OF IDH MUTANT 1p19q NON-CODELETED GLIOMAS USING THE T2-FLAIR MISMATCH SIGN
Authors: Martha Foltyn, Karen Natalia Nieto Taborda, Ulf Neuberger, Annekathrin Reinhardt, Gianluca Brugnara, Andreas Unterberg, Jürgen Debus, Christel Herold-Mende, Andreas von Deimling, Wolfgang Wick, Martin Bendszus, Philipp Kickingereder
Journal: Neuro-Oncology (2019)

Abstract OBJECTIVE To assess the validity and pathophysiology of the T2/FLAIR mismatch sign for non-invasive identification of IDH-mutant 1p/19q non-codeleted glioma. METHODS MRI scans from 408 consecutive patients with newly diagnosed glioma (113 lower-grade glioma and 295 glioblastoma) were evaluated for the presence of a T2/FLAIR-mismatch sign (defined as complete/near-complete hyperintense signal on T2w, simultaneous hypointense signal on FLAIR except for a hyperintense peripheral rim) by two independent reviewers. Sensitivity, specificity, accuracy, positive and negative predictive value (PPV, NPV) were calculated to assess the performance of the T2/FLAIR-mismatch sign for identifying IDH-mutant 1p/19q non-codeleted tumors. An exploratory analysis of spatial differences in ADC and rCBV values comparing the FLAIR-hypointense core vs. hyperintense rim in cases with presence of a T2/FLAIR-mismatch sign was performed. RESULTS There was substantial interrater agreement to identify the T2/FLAIR-mismatch sign (Cohen’s Kappa = 0.75 [95% CI 0.57–0.93]). The T2/FLAIR-mismatch sign was present in 12 cases with lower-grade glioma (10.6%), all of them were IDH-mutant, 1p/19q non-codeleted tumors (sensitivity=10.9%, specificity=100%, PPV=100%, NPV=3.0%, accuracy=13.3%). The T2/FLAIR-mismatch sign was not identified in any other molecular subgroup, especially not in any of the IDH-mutant glioblastoma cases (n=5). In tumors with T2/FLAIR-mismatch sign the ADC values were significantly lower in the rim as compared to the core (p=0.0005) whereas there was no difference in rCBV values (p=0.4258). CONCLUSION This study confirms the high specificity of the T2/FLAIR-mismatch sign for non-invasive identification of IDH-mutant 1p/19q non-codeleted gliomas, although sensitivity is low and applicability is limited to lower-grade gliomas. The identified spatial differences in ADC values between the core and rim of tumors with a T2/FLAIR-mismatch sign potentially reflects differences in tumor cellularity and microenvironment.
Mini- Vs. Regular-Dose CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less Fit Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms
Authors: Anna B. Halpern, Megan Othus, Kelda Gardner, Genevieve Alcorn, Mary-Elizabeth M. Percival, Emily M Huebner, Bart L. Scott, Pamela S. Becker, Paul C. Hendrie, Vivian G. Oehler, Elihu H. Estey, Roland B. Walter
Journal: Blood (2019)
Abstract 3294: Superoxide-Dependent Cathepsin Activation System is Associated with Hypertensive Myocardial Remodeling and Represents a Target for Angiotesin II Type 1 Receptor Blocker Therapy
Authors: Xian Wu Cheng, Kenji Okumura, Kohzo Nagata, Hideo Izawa, Koji Obata, Takeshi Sasaki, Aiko Inoue, Takao Nishizawa, Takashi Yamada, Masakazu Kobayashi, Yasuya Inden, Yosuke Murase, Mafumi Kuzuya, Guo-Ping Shi, Toyoaki Murohara, Mitsuhiro Yokota
Journal: Circulation (2007)

Objective: Cathepsin (Cat) activation contributes to tissue remodeling, and increased Cat activity and superoxide production has been observed in the left ventricle (LV) during heart failure (HF). In the present study we tested the hypothesis that superoxide-dependnet Cat activation inhibition prevents LV remodeling and dysfunction in the development of HF associated with hypertension. Methods and Results: We treated 8% salt-loaded Dahl salt-sensitive hypertensive rats (n=10 for each group) with vehicle hydralazine (5 mg/kg/d) E64d (a synthesis Cat inhibitor, 10 mg/kg/d), or olmesartan (OLM, 5 mg/kg/d) for 8 weeks. The rats fed 0.3% salt served as age-matched controls. The abundance of Cat mRNAs and proteins localized in cardiac myocytes (CMCs) and Cat-dependent activities were increased in the LV of HF rats and/or humans, and were reduced by OLM treatment. OLM suppressed the elastic lamina degradation by 56% (n=6, p&lt;0.01) concomitant with decreased local Cat S expression in intracoronary smooth muscle cells (SMCs) and restored the balance of elastin to collagen in the LV tissue of HF rats (HF 4.6 ± 0.9% vs. OLM 15.5 ± 2.1% elastin content/collagen content (%), n=6, P=0.031; control 22 ± 2.1%). Furthermore, OLM suppressed not only angiotensin converting enzyme and angiotensin II type 1 receptor (AT 1 R) and macrophage infiltration but also levels of NADPH oxidase components (p22 phox , gp91 phox , and p47 phox) concomitant with decreased NADPH activity and O 2 − production in LV tissues of HF rats and humans. These changes were accompanied by improved cardiac fibrosis, stiffness, and dysfunction. Interestingly, LV remodeling and dysfunction were partially improved by treatment with E64d. In vitro, H 2 O 2 stimulated Cat S mRNA and protein expression and activity, and these increases were abolished by pretreatment with MnTmPyp (50 μ mol/L) and N-acetylcysteine (5 mmol/L) as well as apocynin (100 μ mol/L) in culture CMCs (n=6, p&lt;0.01). Conclusions: This is the first report showing that Cats are likely to trigger and promote LV remodeling, and that AT 1 R inhibition exerts inhibitory effect on Cat activation system by the inhibition of NADPH oxidase-dependent superoxide anion production, leading to the prevention of cardiac remodeling and dysfunction.
The Complexity of Genotype‐Phenotype Correlations in Hereditary Spherocytosis: A Cohort of 95 Patients
Authors: Annelies van Vuren, Bert van der Zwaag, Rick Huisjes, Nathalie Lak, Marc Bierings, Egbert Gerritsen, Eduard van Beers, Marije Bartels, Richard van Wijk
Journal: HemaSphere (2019)

Hereditary spherocytosis (HS) is a phenotypically and genetically heterogeneous disease. With the increased use of Next Generation Sequencing (NGS) techniques in the diagnosis of red blood cell disorders, the list of unique pathogenic mutations underlying HS is growing rapidly. In this study, we aimed to explore genotype-phenotype correlation in 95 HS patients genotyped by targeted NGS as part of routine diagnostics (UMC Utrecht, Utrecht, The Netherlands). In 85/95 (89%) of patients a pathogenic mutation was identified, including 56 novel mutations.
HOUT-12. RETURN TO WORK FOLLOWING AWAKE SURGERY FOR GLIOMAS IN SPEECH-ELOQUENT AREAS
Authors: Marie-Therese Forster, Irina Lortz, Volker Seifert, Christian Senft
Journal: Neuro-Oncology (2019)

Abstract OBJECTIVE Pursuing a profession is an indispensable component of human happiness. The aim of this study was to analyze patients′ professional, socio-economic and psychological outcomes besides their neuro-oncological and functional evaluation after awake surgery for gliomas in eloquent areas. METHODS The neuro-oncological and functional outcomes of patients with gliomas other than glioblastoma undergoing awake surgery during a period of 5 years were prospectively assessed within our routine oncological follow-up. Repercussions of the disease on their professional status, socio-economic situation, and neurocognitive function were evaluated retrospectively with structured interviews. RESULTS We analyzed data of 37 patients with gliomas (3 WHO Grade I, 6 WHO grade II, 28 WHO grade III). Gross total and subtotal tumor resections were performed in 20 (54.1%) and 11 (29.7%) patients, respectively, whereas in 7 patients (16.2%) resection had to remain partial. Median follow up was 24.1 months (range: 5–61 months). 31 patients (83.8%) had stable disease, 2 (5.4%) patients suffered from tumor progression and 4 (10.8%) patients died. Prior to surgery, all but one patient were employed. At the time of analysis, 24 (72.7%) of 33 alive patients had resumed their profession. 5 patients (15.2%) were on incapacity pension, 2 patients were on sick leave, and 2 had retired. The median time until return to work following surgery was 5.9 ±4.6 months. Young age (&lt; 40 years) was the only factor statistically significantly associated with the ability to return to work (p&lt; 0.001). CONCLUSION Despite brain tumor surgery in eloquent regions, the majority of patients with WHO grade II or III gliomas are able to return to work. Employing awake techniques in order to preserve neurological function is of utmost relevance for individual patients′ quality of life and may also decrease the economic burden due to work loss frequently encountered in glioma patients.
A retrospective, quantitative assessment of disease burden in patients with leptomeningeal metastases from non-small-cell lung cancer
Authors: Kathryn S Nevel, Natalie DiStefano, Xuling Lin, Anna Skakodub, Shahiba Q Ogilvie, Anne S Reiner, Elena Pentsova, Adrienne Boire
Journal: Neuro-Oncology (2019)

Improvements in detection and molecular characterization of leptomeningeal metastasis from lung cancer (LC-LM) coupled with cerebrospinal fluid (CSF)-penetrating targeted therapies have altered disease management. A barrier to formal study of these therapies in LM is quantification of disease burden. Also, outcomes of patients with targetable mutations in LC-LM are not well defined. This study employs molecular and radiographic measures of LM disease burden and correlates these with outcome.
The Ire of IRE1α: Overexpression of IRE1α at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1α Expression Is Predictive of Therapy Resistance
Authors: Scott R. Goldsmith, Mark A. Fiala, Mark A. Schroeder, Tanya M. Wildes, Armin Ghobadi, Ravi Vij, Keith E. Stockerl-Goldstein
Journal: Blood (2019)
Rovsing's Sign
Authors: J. Ferguson
Journal: BMJ (1956)

<h3>Introduction</h3> Acute necrotising Pancreatitis with parenchymal and peripancreatic necrosis when infected results in significant morbidity and a high risk for mortality.Despite the advent of better accessories and equipment including the LAMS (lumen opposing metal stents), the timing of the intervention is always a question of debate. We are presenting this video capsule on early multimodal intervention in an adult male, with severe, infected extensive pancreatic necrotic collection. <h3>Method</h3> This is a video case report describing the early multimodal therapy using Linear array echo-endoscope guided pseudocyst drainage with lumen opposing metal stent (Nagi<sup>TM</sup> stent) and subsequent necrosectomy with gastroscope and polypectomy snare. Patient also had bilateral percutaneous pigtail drain placed under transabdominal ultrasound guidance. <h3>Results</h3> A 30 year old adult male patient with Acute severe Pancreatitis, aetiology being alcohol. Patient was referred from a district hospital in view of severe necrotising pancreatitis.On week 3rd,a repeat abdominal imaging showed extensive pancreatic necrotic collection extending from the retroperitoneal space upto the pelvis and paracolic gutter with evidence of multiple air pockets within, no clear wall was formed yet around the necrotic collection. EUS guided cystogastrotomy using lumen opposing metal stent (Nagi<sup>TM</sup> stent) was placed transmurally and simultaneously percutaneous transabdominal ultrasound guided pigtail were placed bilaterally to drain the paracolic gutters. Subsequently necrosectomy was performed over three sessions spaced over two weeks in between.Patient did not develop bleeding or any other major complications and was under cover of broad spectrum antibiotics for infected pancreatic necrosis. Healthy granulation tissue noted during the last session and the percutaneous drain was removed subsequently.Patient clinically improved and on followup. <h3>Conclusion</h3> Early minimally invasive multimodal Endotherapy in the setting of infected extensive pancreatic necrosis facilitates to improve clinical outcome with less morbidity.Larger prospective randomised control trials comapring early and delayed interventions are necessary to validate the findings. <h3>Reference</h3> . Freeman ML, Werner J, van Santvoort HC, et al. International Multidisciplinary Panel of Speakers and Moderators. Interventions for necrotizing pancreatitis: summary of a multidisciplinary consensus conference. Pancreas2012;41(8):1176–1194 <h3>Disclosure of Interest</h3> None Declared
A Multicenter, Italian Trial of Early Iron Chelation Therapy with Low Dose Deferasirox (Exjade®) in Patients with Low/Intermediate-1 Risk MDS at the Beginning of Transfusional Story
Authors: Emanuele Angelucci, Mario Capasso, Matteo Giovanni Della Porta, Gian Luca Forni, Domenico Girelli, Esther Natalie Oliva, Federica Pilo, Marino Clavio, Marta Riva, Annamaria Pelizzari, Pasquale Niscola, Daniela Cilloni, Gianni Binotto, Elena Crisà, Valeria Santini
Journal: Blood (2019)
Cleansing of Hospital Blankets
Authors: C. G. A. Thomas, J. Liddell, D. S. Carmichael
Journal: BMJ (1958)

BsIrnJouRNALTABLE I.-Cl.tetani in Samples of Air (690 cubic feet-19.5 cubic metres) Samples Toa Place Yielding Samples Days Cl. tetani
Hepatic Leukemia Factor Is Critical for Hematopoietic Stem Cells and Promotes MLL-AF9 Acute Myeloid Leukemia
Authors: Aurelie Baudet, Karolina Paulina Komorowska, Hultmark Simon, Marcus Järås, Marion Chapellier, Gunnar Juliusson, Mattias Magnusson
Journal: Blood (2019)
Does Guideline-Directed Medical Therapy for Heart Failure Offer Benefits After LVAD Placement?—A Call for a Randomized Clinical Trial
Authors: Clyde W. Yancy, Gregg C. Fonarow, Adrian F. Hernandez
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Roxadustat (FG4592; ASP1517; AZD9941) in the Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (LR-MDS) and Low Red Blood Cell (RBC) Transfusion Burden (LTB)
Authors: David H. Henry, John Glaspy, Rosemary Anne Harrup, Moshe Mittelman, Amy Zhou, Charles Bradley, Gopal Saha, Pamela Bartels, Leong Robert, Kin-Hung P Yu
Journal: Blood (2019)
HOUT-19. THE SHORT-TERM OVERALL SURVIVAL ASSOCIATED WITH SINGLE- VS. MULTI-AGENT CHEMOTHERAPEUTIC REGIMENS FOR 1p/19q-CODELETED WHO GRADE III ANAPLASTIC OLIGODENDROGLIOMAS: A NATIONAL EVALUATION
Authors: Mehdi Touat, Maya Harary, Vasileios Kavouridis, Timothy Smith, Bryan Iorgulescu
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Although diffuse gliomas of oligodendrocytic lineage demonstrate chemosensitivity, the survival outcomes associated with single- (i.e. temozolomide; TMZ) or multi-agent (i.e. PCV) chemotherapy regimens remain uncertain for anaplastic oligodendrogliomas (AO). METHODS Patients presenting between 2010–2016 with 1p/19q-codeleted WHO grade III AO were identified by ICD-O3 and site-specific factors from the National Cancer Database, which comprises &gt;70% of cancers newly-diagnosed in the U.S. Predictors of receiving first-line single- vs. multi-agent chemotherapy were assessed by multivariable logistic regression. Overall survival (OS) was estimated by Kaplan-Meyer approaches and evaluated by multivariable Cox regression. RESULTS There were 952 patients with 1p/19q-codeleted WHO grade III AO and complete first-line chemotherapy data, with: 13.9% (n=132) no-, 75.0% (n=714) single-, and 11.1% (n=106) multi-agent chemotherapy. In logistic regression of chemotherapy-treated AOs, more recent diagnosis was associated with higher multi-agent (OR=1.48/year, 95%CI=1.25–1.74, p&lt; 0.001) rates; otherwise there were no associations of single- vs. multi-agent chemotherapy with patient sex, age-at-diagnosis, race, insurance status (reference=privately insured), comorbidity index, tumor greatest dimension, tumor location (reference=frontal lobe) or crossing of midline, nor with radiotherapy or EOR (all p &gt;0.05). Multi-agent usage rose from 3.6% in 2010 to 24.3% in 2016. Median follow-up was 34.9mos (IQR=18.8–54.8). The unadjusted 5yr-OS rate was 57.4% (95%CI=43.5–69.1) for no chemotherapy, 72.1% (95%CI=67.1–76.5) for single-agent, and 77.5% (95%CI=59.9–88.1) for multi-agent. Cox regression (adjusting for the above variables of radiotherapy and EOR, patient demographics, and tumor characteristics) demonstrated no significant OS difference between single- and multi-agent (HR=0.91, 95%CI=0.38–2.15, p=0.82) chemotherapy. CONCLUSIONS In a national database of AOs managed in the ‘real-world’ setting, there is increasing utilization of multi-agent (i.e. PCV) chemotherapy; but no significant difference in risk-adjusted short-term mortality (i.e. ~3-5yrs after diagnosis) between first-line multi- and single-agent (i.e. TMZ) chemotherapy. These findings provide preliminary data while we await the long-term PFS and OS results from the CODEL trial.
Potency Equated Porcine and Bovine Mucosal Heparin Are Bioequivalent in Terms of Biochemical and Pharmacological Effects
Authors: Nausheen Baig, Ahmed Kouta, Fakiha Siddiqui, Ambar Farooqui, Debra Hoppensteadt, Walter Jeske, Omer Iqbal, Cassie Bacher, Sharan Krishnappan, Jawed Fareed
Journal: Blood (2019)
Treatment of Upper Extremity Deep Vein Thrombosis with Apixaban and Rivaroxaban
Authors: Damon E. Houghton, Jordan Cochuyt, David O. Hodge, Danielle Vlazny, Ana I Casanegra, Lisa Peterson, David A Froehling, Robert D. McBane, Waldemar E. Wysokinski
Journal: Blood (2019)
Oral contraceptives and breast lesions [letter]
Authors: Fasal E, Paffenbarger Rs
Journal: JNCI Journal of the National Cancer Institute (1977)

In reply to a query on an earlier study by the same authors (Journal of the National Cancer Institute 55: 767-773 1975) in which evidence was found that oral contraceptives (OCs) increase the risk of breast cancer in women with benign breast  disease the authors report that the women taking OCs in their study did not do so by way of treatment for the breast condition but for entirely other reasons. The risk of breast cancer in these women increased 11-fold when OCs were taken for 6 years or longer. The authors reaffirm their recommendation against the use of OCs by women with fibrocystic disease and other benign breast lesions.
Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study
Authors: Georg Nickenig, Marcel Weber, Philipp Lurz, Ralph Stephan von Bardeleben, Marta Sitges, Paul Sorajja, Jörg Hausleiter, Paolo Denti, Jean-Noël Trochu, Michael Näbauer, Abdellaziz Dahou, Rebecca T Hahn
Journal: The Lancet (2019)
Diagnostic Assessment Strategies and Disease Subsets in Giant Cell Arteritis: Data From an International Observational Cohort
Authors: K. Bates Gribbons, Cristina Ponte, Anthea Craven, Joanna C. Robson, Ravi Suppiah, Raashid Luqmani, Richard Watts, Peter A. Merkel, Peter C. Grayson
Journal: Arthritis & Rheumatology (2019)

Objective Diagnostic assessment in giant cell arteritis ( GCA ) is rapidly changing as vascular imaging becomes more available. This study was undertaken to determine if clinical GCA subsets have distinct profiles or reflect differential diagnostic assessments. Methods Patients were recruited from an international cohort and divided into 4 subsets based on a temporal artery ( TA ) abnormality (positive TA biopsy [ TAB ] or halo sign on TA ultrasound [ TA ‐ US ]) and/or evidence of large vessel ( LV ) involvement on imaging: 1) both TA abnormality and LV involvement ( TA +/ LV + GCA ); 2) TA abnormality without LV involvement ( TA +/ LV − GCA ); 3) LV involvement without TA abnormality ( TA −/ LV + GCA ); and 4) clinically diagnosed GCA without LV involvement or TA abnormality ( TA −/ LV − GCA ). Results Nine hundred forty‐one patients with GCA were recruited from 72 international study sites. Most patients received multiple forms of diagnostic assessment, including TAB (n = 705 [75%]), TA ‐ US (n = 328 [35%]), and LV imaging (n = 534 [57%]). Assessment using TAB , TA ‐ US , and LV imaging confirmed the diagnosis of GCA in 66%, 79%, and 40% of cases, respectively. GCA subsets had distinct profiles independent of diagnostic assessment strategies. TA +/ LV − were the most common subset (51%), with a high burden of cranial ischemia. Those in the TA −/ LV − subset (26%) had a high prevalence of cranial ischemia and musculoskeletal symptoms. Patients in the TA −/ LV + subset (12%) had prevalent upper extremity vascular abnormalities and a low prevalence of vision loss, and those in the TA +/ LV + subset (11%) were older and had a high prevalence of cranial ischemia, constitutional symptoms, and elevated acute‐phase reactant levels. Conclusion Vascular imaging is increasingly incorporated into the diagnostic assessment of GCA and identifies clinical subsets of patients based on involvement of temporal and extracranial arteries.
A roadmap for sustainably governing the global antimicrobial commons
Authors: Susan Rogers Van Katwyk, Manica Balasegaram, Pete Boriello, Jeremy Farrar, Alberto Giubilini, Mark Harrison, Marie-Paule Kieny, Claas Kirchhelle, Joanne Liu, Kevin Outterson, Muhammad Ali Pate, Mathieu Poirier, John-Arne Røttingen, Julian Savulescu, Rebecca Sugden, Visanu Thamlikitkul, Isaac Weldon, Sally Davies, Steven J Hoffman
Journal: The Lancet (2019)
FT538: Preclinical Development of an Off-the-Shelf Adoptive NK Cell Immunotherapy with Targeted Disruption of CD38 to Prevent Anti-CD38 Antibody-Mediated Fratricide and Enhance ADCC in Multiple Myeloma When Combined with Daratumumab
Authors: Ryan Bjordahl, Svetlana Gaidarova, Karrune Woan, Frank Cichocki, Greg Bonello, Megan Robinson, Chelsea Ruller, Mochtar Pribadi, Jason Dinella, Lauren Fong, Janel Huffman, Hui-yi Chu, Tom Lee, Ramzey Abujarour, Dan S Kaufman, Karl-Johan Malmberg, Jeffrey S. Miller, Bahram Valamehr
Journal: Blood (2019)
Abstract 15574: Low Vascular Endothelial Growth Factor-c Was a Predictor for Cardiovascular Events in Patients With Atrial Fibrillation: A Subanalysis of the Anox Study
Authors: Moritake Iguchi, Masahiro Suzuki, Morihiro Matsuda, Yoichi Ajiro, Tsuyoshi Shinozaki, Satoru Sakagami, Kazuya Yonezawa, Masatoshi Shimizu, Junichi Funada, Takashi Takenaka, Yukiko Morita, Toshihiro Nakamura, Kazuteru Fujimoto, Hiromi Matsubara, Toru Kato, Takashi Unoki, Daisuke Takagi, Shuichi Ura, Kyoma Wada, Nobutoyo Masunaga, Mitsuru Ishii, Hajime Yamakage, Akira Shimatsu, Kazuhiko Kotani, Noriko Satoh-Asahara, Mitsuru Abe, Masaharu Akao, Koji Hasegawa, Hiromichi Wada
Journal: Circulation (2018)

Background: Atrial fibrillation (AF) and coronary artery disease (CAD) share common risk factors and often coexist. However the data on the impact of CAD on the prognosis of AF patients was limited...
A New Promising Third Generation CAR-CD30 T-Cell Therapy for CD30+ Lymphoma
Authors: Biagio De Angelis, Marika Guercio, Domenico Orlando, Stefano Di Cecca, Matilde Sinibaldi, Iolanda Boffa, Simona Caruso, Zeinab Abbaszadeh, Antonio Camera, Cembrola Biancamaria, Katia Bovetti, Ignazio Caruana, Francesca Del Bufalo, Pietro Merli, Luciana Vinti, Katia Girardi, Annalisa Ruggeri, Rita De Vito, Concetta Quintarelli, Franco Locatelli
Journal: Blood (2019)